Coronaviridae

Media Advisory: This morning, the COVID-19 Immunity Task Force (CITF) and Statistics Canada will release final results from Canada’s most representative antibody study

Retrieved on: 
Tuesday, July 6, 2021
Medical specialties, Coronaviridae, Medicine, COVID-19 Immunity Task Force, Clinical pathology, Epidemiology, Serology, Severe acute respiratory syndrome coronavirus, COVID-19

MONTREAL, July 06, 2021 (GLOBE NEWSWIRE) -- The COVID-19 Immunity Task Force (CITF) and Statistics Canada will be releasing final results this morning from Canadas most representative study to date investigating how many Canadians have antibodies to SARS-CoV-2, the virus causing COVID-19.

Key Points: 
  • MONTREAL, July 06, 2021 (GLOBE NEWSWIRE) -- The COVID-19 Immunity Task Force (CITF) and Statistics Canada will be releasing final results this morning from Canadas most representative study to date investigating how many Canadians have antibodies to SARS-CoV-2, the virus causing COVID-19.
  • This morning, results will be announced.
  • Spokespeople from Statistics Canada will be available to discuss and explain the data and methodology.
  • A spokesperson from the CITF will be available to explain the data within the context of the pandemic and what it means for Canada.

ABT PARTNERS WITH CDC ON NEJM STUDY SHOWING COVID-19 VACCINES EFFECTIVE AT PREVENTING AND MODERATING EFFECTS OF INFECTIONS

Retrieved on: 
Thursday, July 1, 2021
Coronaviridae, Sarbecovirus, Zoonoses, Bat virome, COVID-19, Occupational safety and health, Public health, Severe acute respiratory syndrome

Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.

Key Points: 
  • Abt Associates partnered with the CDC on the study, which showed that the vaccines not only prevent SARS-CoV-2 infections but also reduce serious symptoms among those with breakthrough infections despite vaccination.
  • A group of 3,975 healthcare personnel, first responders, and other essential and frontline workers completed weekly SARS-CoV-2 nasal swab testing from December 14, 2020, to April 10, 2021.
  • Such studies increase the publics knowledge and understanding of COVID-19, adds Project Director Danielle Hunt, an Abt vice president and senior epidemiologist.
  • Abt Associates is a global consulting and research firm that uses data and bold thinking to improve the quality of people's lives.

Atea’s AT-527, an Oral Antiviral Drug Candidate, Reduces Viral Replication in Hospitalized Patients with COVID-19 in Phase 2 Interim Analysis

Retrieved on: 
Wednesday, June 30, 2021
Coronaviridae, Sarbecovirus, Severe acute respiratory syndrome coronavirus, Antiviral drug, Severe acute respiratory syndrome

Roche and Atea are jointly developing AT-527, an oral direct-acting antiviral (DAA) agent derived from Ateas purine nucleotide prodrug platform.

Key Points: 
  • Roche and Atea are jointly developing AT-527, an oral direct-acting antiviral (DAA) agent derived from Ateas purine nucleotide prodrug platform.
  • The interim analysis of the Phase 2 study included data from 70 hospitalized, high-risk patients with COVID-19 of which data from 62 patients were evaluable for virology analysis.
  • AT-527s SARS-CoV-2 potent antiviral activity was also observed in patients with higher baseline viral loads above the median of 5.26 log10 as compared to placebo.
  • We are very pleased with the potent antiviral activity of AT-527 demonstrated by the rapid inhibition of SARS-CoV-2 replication.

RedHill Biopharma's Opaganib Inhibits COVID-19 Variants in Preclinical Study

Retrieved on: 
Monday, June 28, 2021
Coronaviridae, COVID-19 vaccines, Clinical trials, Health, Variants of SARS-CoV-2, COVID-19

Phase 2 study data, opaganib's global 475-patient Phase 2/3 study in hospitalized patients with COVID-19 is fully enrolled and is expected to be completed in the coming weeks.

Key Points: 
  • Phase 2 study data, opaganib's global 475-patient Phase 2/3 study in hospitalized patients with COVID-19 is fully enrolled and is expected to be completed in the coming weeks.
  • Preliminary results showed potent inhibition of both the Beta and Gamma variants by opaganib at non-cytotoxic doses.
  • This means we expect opaganib to similarly work against other emerging COVID-19 variants, including the Delta (Indian) variant.
  • The global Phase 2/3 study of opaganib in COVID-19 has previously received four independent DSMB recommendations to continue following unblinded safety reviews and a futility review.

DeepVerge plc: Microtox® PD claims world first live data alerts of SARS-Cov-2 in wastewater treatment plants

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Public health, COVID-19, Occupational safety and health, Zoonoses, Severe acute respiratory syndrome, Wastewater-based epidemiology

YORK, England, June 24, 2021 /PRNewswire/ -- DeepVerge (LSE: DVRG.L), today announces the successful completion of Phase 3 field trials in which Microtox PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites.

Key Points: 
  • YORK, England, June 24, 2021 /PRNewswire/ -- DeepVerge (LSE: DVRG.L), today announces the successful completion of Phase 3 field trials in which Microtox PD achieved real-time detection and transmission of data, specific to SARS-CoV-2, in wastewater treatment plants at multiple sites.
  • "The successful completion of the Phase 3 field trials clearly demonstrates the capability and value of Microtox PD to identify dangerous pathogens, including SARS-CoV-2, in real-time.
  • By establishing a permanent anonymised mass surveillance of wastewater, DeepVerge claims a world first real-time defence against this global pandemic.
  • The installation of Microtox PD wastewater units will enable live data to simultaneously identify the source of COVID-19 cases as well as identify COVID-19 clusters with the ability to indicate the size of each cluster.

LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Branches of biology, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, COVID-19, Severe acute respiratory syndrome coronavirus 2, Peplomer, Rapid antigen test, Severe acute respiratory syndrome coronavirus, SARS-CoV-2 Iota variant

LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

Key Points: 
  • LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.
  • SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time.
  • The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants.
  • Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein.

 LumiraDx High Sensitivity Point of Care Antigen Test Detects Against Leading Variants of Concern including Alpha, Beta, Gamma, and Delta

Retrieved on: 
Thursday, June 24, 2021
Coronaviridae, Branches of biology, Medicine, Sarbecovirus, Variants of SARS-CoV-2, Zoonoses, COVID-19, Severe acute respiratory syndrome coronavirus 2, Peplomer, Rapid antigen test, Severe acute respiratory syndrome coronavirus, SARS-CoV-2 Iota variant

LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.

Key Points: 
  • LONDON, June 24, 2021 /PRNewswire/ --Today, LumiraDx, a next-generation point of care (POC) diagnostics testing company ("LumiraDx" or "Company"), confirmed that the LumiraDx SARS-CoV-2 Ag Test detects major global SARS-CoV-2 variants including Alpha, Beta, Gamma, Delta and Epsilon variants.
  • SARS-CoV-2, like other viruses, is constantly mutating, and becoming more diverse with new variants of the virus occurring over time.
  • The LumiraDx SARS-CoV-2 Antigen test is well positioned to detect these existing and new variants.
  • Unlike PCR, the LumiraDx SARS-CoV-2 Ag Test uses antibodies, not nucleic acid based-primers, to capture SARS-CoV-2 nucleocapsid antigen, not the spike protein.

Draper Delivers a First by Infecting Lung-on-Chip with Wildtype SARS-CoV-2 Virus

Retrieved on: 
Wednesday, June 23, 2021
Coronaviridae, Medical specialties, Zoonoses, Medicine, Sarbecovirus, Severe acute respiratory syndrome coronavirus 2, Severe acute respiratory syndrome coronavirus, COVID-19, Severe acute respiratory syndrome, Virus, Viral disease, Coronavirus

"In SARS-CoV-2 research, organ-on-chip is emerging as a powerful method for scientists to assess the potential effects of drugs in humans.

Key Points: 
  • "In SARS-CoV-2 research, organ-on-chip is emerging as a powerful method for scientists to assess the potential effects of drugs in humans.
  • "The door is now open for using naturally circulating viruses to develop and screen therapies for COVID-19 using the best method availableorgan-on-a-chip."
  • In the study, the researchers investigated viral infection kinetics of the SARS-CoV-2 virus in the PREDICT96-ALI platform in a BSL-3 laboratory environment.
  • Results with naturally occurring, or wildtype, virus are more relevant to the infection and replication process that causes disease in humans.

Study finds schools are not at higher risk for COVID-19

Retrieved on: 
Tuesday, June 22, 2021
Coronaviridae, Medicine, Health sciences, Sarbecovirus, Zoonoses, Epidemiology, Infectious diseases, Occupational safety and health, COVID-19, Severe acute respiratory syndrome, Subclinical infection, COVID-19 testing

Even when we account for asymptomatic infection using sensitive blood tests, the risk of SARS-CoV-2 being transmitted in schools overall remains very low, says Dr. David Goldfarb, co-investigator and lead author of the article.

Key Points: 
  • Even when we account for asymptomatic infection using sensitive blood tests, the risk of SARS-CoV-2 being transmitted in schools overall remains very low, says Dr. David Goldfarb, co-investigator and lead author of the article.
  • In this study, school staff reported consistent rates of positive viral tests which are similar to the Vancouver School District1.3 per cent.
  • These results reaffirm that with the protocols we have in place, schools are safe places to teach and learn.
  • This study highlights that COVID-19 in a school setting typically mirrors transmission from family and community contacts.

Innovation Pharma Announces New Brilacidin Antiviral Research on Non-SARS-CoV-2 Endemic Viral Diseases to be Presented at the 2021 Military Health System Research Symposium

Retrieved on: 
Friday, June 18, 2021
Coronaviridae, Sarbecovirus, Health sciences, Medicine, Zoonoses, Antiviral drugs, COVID-19 pandemic in Russia, Coronavir, Severe acute respiratory syndrome, Brilacidin, COVID-19

The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.

Key Points: 
  • The MHSRS is an annual four-day scientific symposium sponsored by the U.S. Department of Defense.
  • The presentation on Brilacidin will be part of the Development of New Front Line Therapies to Prevent and Treat Non-SARS-CoV-2 Endemic Viral Diseases Breakout Session.
  • Brilacidin is the only non-peptidic defensin-mimetic drug candidate currently in a clinical trial as a treatment for SARS-CoV-2, the coronavirus responsible for COVID-19.
  • A more complete description of these risk factors is included in the Companys filings with the Securities and Exchange Commission.